17:33 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Lilly's mirikizumab improves clinical remission in Phase II for ulcerative colitis

Eli Lilly and Co. (NYSE:LLY) reported in June that 200 mg IV mirikizumab (LY3074828) met the primary endpoint of improving clinical remission rate at week 12 vs. placebo in a Phase II trial to treat...
17:06 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals July 26, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended...
22:08 , Jul 27, 2018 |  BC Extra  |  Company News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals Friday, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval...
18:29 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Sun's IL-23 psoriasis mab approved by FDA

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit...
18:41 , Mar 21, 2018 |  BC Extra  |  Company News

Sun's IL-23 mAb gets FDA approval for psoriasis

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit...
18:38 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

J&J reports 72-week data for Tremfya in plaque psoriasis

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported 72-week data from the Phase III VOYAGE 2 trial of Tremfya guselkumab (CNTO 1959) to treat moderate to severe plaque psoriasis. Tremfya...
18:14 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic lymphocytic leukemia (CLL) Patient sample, cell culture and mouse studies suggest inhibiting IL23P19-IL-23 receptor signaling could help treat CLL. In peripheral blood mononuclear cells (PBMCs) from patients, high levels of IL-23 receptor were...
23:55 , Jul 13, 2017 |  BC Week In Review  |  Company News

Almirall lowers guidance

Almirall S.A. (Madrid:ALM) lowered its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared to 2016, and it guided to EBITDA of...
22:18 , Jul 10, 2017 |  BC Extra  |  Financial News

Almirall sags after lowering guidance

Almirall S.A. (Madrid:ALM) fell €3.21 (25%) to €9.80 on Monday after lowering its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared...
21:00 , Jun 1, 2017 |  BC Week In Review  |  Clinical News

FDA reviewing Sun's psoriasis candidate tildrakizumab

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA accepted for review a BLA for tildrakizumab (MK-3222) to treat moderate to severe plaque psoriasis. The company declined to disclose the PDUFA date. In March, EMA validated...